knowledge -WSS

knowledge

author：focus 2025-09-02 11:48:57 - browse：736

Golden brain and DNA spiral illustration. -- biotech coverage from STAT — Adobe

The dream of being able to pluck a cell therapy off of a freezer shelf and speedily give it to cancer patients is materializing in the cancer world. Now, a new biotech hopes to do the same for patients with neurological conditions.

Kenai Therapeutics closed a $82 million Series A round Thursday co-led by Cure Ventures, The Column Group, and sovereign wealth fund Alaska Permanent Fund Corp. The San Diego-based biotech has big plans for that money — it’s already identified its lead drug candidate for people with Parkinson’s disease, and plans to move into a clinical trial within the next year.

Kenai — pronounced key-nigh — is developing therapies that use induced pluripotent stem cells, or iPSCs. These highly versatile organisms are derived from skin or blood cells and can be transformed into any type of cell. In Parkinson’s, the idea is that these cells would replace damaged neurons.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Harvard scientists, with Google, unveil the most detailed brain map ever

hotspot

focus

WSS

Bird flu in dairy cattle: New measures to control spread to humans

Immunocompromised patients offer clues on chronic Covid

There's an unseen cost to disruptive road

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Scientific mystery highlights the blind spots in genomics databases

FDA sets aggressive timeline for overhauling inspection procedures

focus

knowledge

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

Harvard scientists, with Google, unveil the most detailed brain map ever

Sports medicine is finally prioritizing gender equality

U.K. decision on ALS drug has neurologists, advocates up in arms

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Insurer loopholes limit power of law against surprise medical bills

FDA approval of Sarepta Duchenne genetic therapy gives me hope

First Opinion on colorectal cancer screening: letter and response

Affirmative action in medical school literally saved lives

HPV vaccine, cervical cancer study delivers historic results

knowledge

Dana Farber says 6 studies to be retracted and 31 corrected

Researchers test human milk's ability to repair gut microbiome

Printout prescription drug information shouldn’t go digital

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Mass General Brigham physicians react to latest merger step

Insurer loopholes limit power of law against surprise medical bills

hotspot

hotspot

focus

knowledge